Progestin Treatment for Endometrial Stromal Cells in Adenomyosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00155051 |
Recruitment Status
: Unknown
Verified June 2004 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted
: September 12, 2005
Last Update Posted
: September 12, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Long term treatment of progestin has been demonstrated to have an inhibitory effect on endometrial angiogenesis and the proliferation of endometrial stromal cells. As a result, progestin is now widely employed in the treatment of endometrial cancer, endometrial hyperplasia, and dysfunction uterine bleeding. In the treatment of adenomyosis, however, the beneficial effect of progestin was limited. It might imply that the behavior of endometrial cells in women with adenomyosis is different from that in women without adenomyosis.
Our previous study revealed that the expression of killer inhibitory receptors (KIRs) on NK cells was decreased in eutopic endometrium in women with adenomyosis. It may be a compensatory effect in which the NK cytotoxicity is activated in order to wipe out the abnormal endometrial cells that might go out of the eutopic site of endometrium. It implies that the formation of adenomyosis might be due to “abnormal” endometrial tissues, but not the aberrant local immunological dysfunction in myometrium. This finding is compatible with previous reports in which eutopic endometrium obtained from women with endometriosis or adenomyosis was found to behave differently from endometrium in unaffected women.
In this study, we try to collect endometrial tissues from women with and without adenomyosis, and then purify the endometrial stromal cells from endometrium. The endometrial stromal cells are cultured for 8 days with the supplement of medroxyprogesterone (MPA) or danazol. Quantification of IL-6 and IL-8 mRNA in endometrial cells, and the concentrations of IL-6 and IL-8 in cultured media will be done with real time RT-PCR and ELISA respectively. The expression of different cytokines of endometrial cells in response to progestin might be further elucidated after our experiment.
Condition or disease |
---|
Endometriosis |
Eutopic endometrium was obtained and separated into single endometrial stromal cell (ESC) in women with adenomyosis (study group) and without adenomyosis (control group).
After becoming pre-confluent (covering 80% of the culture well), ESC was cultured for 8 days solely or with the addition of medroxyprogesterone (MPA) or danazol.
ELISA was done to measure IL-6, IL-8, and TNF-alpha concentrations of the culture media.
Real-time quantitative RT-PCR was done to measure IL-6, IL-8, and TNF-alpha RNA levels in ESC.
Study Type : | Observational |
Enrollment : | 45 participants |
Observational Model: | Defined Population |
Observational Model: | Natural History |
Time Perspective: | Cross-Sectional |
Time Perspective: | Prospective |
Study Start Date : | July 2004 |
Study Completion Date : | April 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- women with adenomyosis
- at early- to mid-secretory phases
Exclusion Criteria:
- postmenopausal
- malignancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00155051
Contact: Jehn-Hsiahn Yang, M.D. | 886-2-2312-3456 ext 3210 | jhyang@ha.mc.ntu.edu.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan, 100 | |
Contact: Jehn-Hsiahn Yang, M.D. 886-2-2312-3456 ext 3210 jhyang@ha.mc.ntu.edu.tw | |
Principal Investigator: Jehn-Hsiahn Yang, M.D. |
Principal Investigator: | Jehn-Hsiahn Yang, M.D. | Department of Obstetrics and Gynecology, National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00155051 History of Changes |
Other Study ID Numbers: |
9361700762 NTUH.94S72 |
First Posted: | September 12, 2005 Key Record Dates |
Last Update Posted: | September 12, 2005 |
Last Verified: | June 2004 |
Additional relevant MeSH terms:
Endometriosis Genital Diseases, Female |